Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib dose-ranging trial in resistant chronic phase chronic myeloid leukemia
2014-001617-12Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ponatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Takeda. Primary endpoint: BCR-ABL1 International Scale less than or equal to 1% at 12 months. Started Jul 2015; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2014-001617-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001617-12.